Loading
Paper cited by two bottleneck pages and eleven idea pages, indexed on Europe PMC as PubMed record 35145263 and published in Nature Reviews Drug Discovery; the citing pages link this DOI, which is how the record was matched.
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 35145263 (DOI 10.1038/d41573-022-00030-4). Matched by DOI alone: two bottleneck pages and eleven idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
Two bottleneck pages and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Outcome-based annuity payments for potentially curative one-time therapies, Incentives reward me-too drugs and marginal gains.
Shares A repurposing label pathway with short exclusivity that non-profits can hold, Incentives reward me-too drugs and marginal gains.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares Require head-to-head trials against the best in class for later entrants, Too many combinations to test.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares A repurposing label pathway with short exclusivity that non-profits can hold, Incentives reward me-too drugs and marginal gains.
Shares Hospital-based CAR-T manufacturing at cost through a public network, Incentives reward me-too drugs and marginal gains.